Somatic mutations of TP53, NOTCH1, MYC, and CDKN2A account for the aggressive phenotype of the DLBCL variant, which combines chemoresistance and rapid disease kinetics (Fig. 1) [4–6]. Here, CDKN2A is linked to diffuse large B-cell lymphoma.